Key result
Hybrid coronary revascularisation matches CABG for long-term MACCE while reducing complications and expediting recovery.
Why the study?
Although CABG offers superior long-term benefit in selected CAD patients due to internal thoracic artery grafting, patients frequently prefer PCI for its less invasive nature and faster recovery. Hybrid coronary revascularisation combines minimally invasive bypass with PCI to unite internal thoracic artery prognostic benefits with the recovery profile of PCI.
Does hybrid coronary revascularisation (combining minimally invasive surgical arterial grafting with PCI) achieve comparable long-term MACCE and survival outcomes to conventional CABG while improving recovery and reducing morbidity in selected patients with multivessel coronary artery disease?
Does hybrid coronary revascularisation (combining minimally invasive surgical arterial grafting with PCI) achieve comparable long-term MACCE and survival outcomes to conventional CABG while improving recovery and reducing morbidity in selected patients with multivessel coronary artery disease?
Hybrid coronary revascularisation combines the long-term survival benefit of minimally invasive LITA/BITA grafting with the rapid recovery of PCI for non-LAD vessels, offering a promising sternal-sparing strategy for multivessel CAD that warrants validation in large randomized trials.
Answers are grounded in this paper and cite their sources.
Supports hybrid revascularisation in selected patients; leaves open large randomized trials to confirm reproducibility.
In selected patients, coronary artery bypass grafting (CABG) offers superior long-term benefit to percutaneous coronary intervention (PCI) in the treatment of coronary artery disease (CAD). This is largely due to the effectiveness of the left internal thoracic artery (LITA) to left anterior descending (LAD) artery bypass. Patients, however, frequently prefer PCI because of its less invasive nature, faster recovery, and comparable short-term outcomes. Hybrid coronary revascularisation (HCR) combines minimally invasive bypass with PCI using contemporary techniques and modern drug-eluting stents. It aims to unite the prognostic benefit of the LITA + /- RITA graft(s) with PCI’s recovery profile and comparable outcomes in non-LAD saphenous vein bypasses. In this article, we review the biological rationale for LITA and bilateral ITA use, the historical evolution of HCR, current guideline recommendations and practical issues around the timing and sequencing of interventions. In addition, we discuss how the integration of robotic technology facilitates sternal-sparing, multi-arterial approaches that may enable HCR to evolve from a niche to the final destination therapy.
No takes yet. Share an insight, caveat, or question.
Luke et al. (2026) conducted a review in Coronary artery disease (CAD). Hybrid coronary revascularisation (HCR) combining minimally invasive LITA +/- RITA bypass with PCI vs. Conventional coronary artery bypass grafting (CABG) or multivessel percutaneous coronary intervention (PCI) was evaluated on Major adverse cardiovascular and cerebral events (MACCE). Hybrid coronary revascularisation achieves long-term MACCE rates comparable to conventional CABG while expediting recovery and reducing perioperative complications in selected multivessel CAD patients.
Synapse has enriched 10 related papers. Consider them for comparative context: